Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Status:
Recruiting
Trial end date:
2023-12-24
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard
of care treatment regimen, including systemic therapy in subjects with Netherton syndrome